Transcriptional characteristics of CD4+ T cells in multiple sclerosis: Relative lack of suppressive populations in blood

Multiple Sclerosis Journal

Volumn 17, Issue 1, 2011, Pages 57-66

  Edstrom M ^a   Mellergard J ^a   Mjosberg J ^a   Jenmalm, M C ^a   Vrethem, M ^a   Press, R ^b   Dahle, C ^a   Ernerudh, J ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

EBI3; FOXP3; multiple sclerosis; RORC; T cells; transcription factors

Indexed keywords

BETA INTERFERON; EPSTEIN BARR VIRUS INDUCED 3 PROTEIN; MESSENGER RNA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CELL COUNT; CELL POPULATION; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOREGULATION; MALE; MULTIPLE SCLEROSIS; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH1 CELL; TH2 CELL;

EID: 78650990962     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510381256     Document Type: Article

References (51)

1. McFarland HF and Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nature immunology 2007 ; 8 (9). 913-919.
2. Lublin FD and Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 ; 46 (4). 907-911.
3. Thompson AJ, Montalban X., Barkhof F., Brochet B., Filippi M., Miller DH, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Annals of neurology 2000 ; 47 (6). 831-835. (Pubitemid 30390209)
4. Dyment DA, Herrera BM, Cader MZ, Willer CJ, Lincoln MR, Sadovnick AD, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Human molecular genetics 2005 ; 14 (14). 2019-2026.
5. Lincoln MR, Montpetit A., Cader MZ, Saarela J., Dyment DA, Tiislar M., et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nature genetics 2005 ; 37 (10). 1108-1112.
6. Matesanz F., Caro-Maldonado A., Fedetz M., Fernandez O., Milne RL, Guerrero M., et al. IL2RA/CD25 polymorphisms contribute to multiple sclerosis susceptibility. Journal of neurology 2007 ; 254 (5). 682-684.
7. Teutsch SM, Booth DR, Bennetts BH, Heard RN and Stewart GJ Identification of 11 novel and common single nucleotide polymorphisms in the interleukin-7 receptor-alpha gene and their associations with multiple sclerosis. Eur J Hum Genet 2003 ; 11 (7). 509-515.
8. Traugott U., Reinherz EL and Raine CS Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science (New York, NY 1983 ; 219 (4582). 308-310.
9. Mosmann TR, Cherwinski H., Bond MW, Giedlin MA and Coffman RL Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986 ; 136 (7). 2348-2357.
10. de Waal Malefyt R., Figdor CG, Huijbens R., Mohan-Peterson S., Bennett B., Culpepper J., et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 1993 ; 151 (11). 6370-6381.
11. Wang ZE, Reiner SL, Zheng S., Dalton DK and Locksley RM CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. The Journal of experimental medicine 1994 ; 179 (4). 1367-1371.
12. Curtis MM and Way SS Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 2009 ; 126 (2). 177-185.
13. Kao CY, Chen Y., Thai P., Wachi S., Huang F., Kim C., et al. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NFkappaB signaling pathways. J Immunol 2004 ; 173 (5). 3482-3491.
14. Shier P., Hofstra CL, Ma XJ, Wu Y., Ngo K. and Fung-Leung WP Tbt-1, a new T-box transcription factor induced in activated Th1 and CD8+ T cells. Immunogenetics 2000 ; 51 (10). 771-778.
15. Szabo SJ, Kim ST, Costa GL, Zhang X., Fathman CG and Glimcher LH A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000 ; 100 (6). 655-669.
16. Zheng W. and Flavell RA The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997 ; 89 (4). 587-596.
17. Ivanov II, McKenzie BS, Zhou L., Tadokoro CE, Lepelley A., Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006 ; 126 (6). 1121-1133.
18. Sakaguchi S., Sakaguchi N., Asano M., Itoh M. and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995 ; 155 (3). 1151-1164.
19. Fontenot JD, Gavin MA and Rudensky AY Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature immunology 2003 ; 4 (4). 330-336.
20. Collison LW, Workman CJ, Kuo TT, Boyd K., Wang Y., Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007 ; 450 (7169). 566-569.
21. Niedbala W., Wei XQ, Cai B., Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. European journal of immunology 2007 ; 37 (11). 3021-3029.
22. Williams LM and Rudensky AY Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nature immunology 2007 ; 8 (3). 277-284.
23. Yang J., Yang M., Htut TM, Ouyang X., Hanidu A., Li X., et al. Epstein-Barr virus-induced gene 3 negatively regulates IL- 17, IL - 22 and RORgamma t. European journal of immunology 2008 ; 38(5): 1204-1214.
24. Cua DJ, Sherlock J., Chen Y., Murphy CA, Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003 ; 421 (6924). 744-748.
25. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006 ; 177 (1). 566-573.
26. McDonald WI, Compston A., Edan G., Goodkin D., Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of neurology 2001 ; 50 (1). 121-127.
27. Roxburgh RH, Seaman SR, Masterman T., Hensiek AE, Sawcer SJ, Vukusic S., et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005 ; 64 (7). 1144-1151.
28. Mjosberg J., Svensson J., Johansson E., Hellstrom L., Casas R., Jenmalm MC, et al. Systemic reduction of functionally suppressive CD4dimCD25highFoxp3+ Tregs in human second trimester pregnancy is induced by progesterone and 17{beta}-estradiol. J Immunol 2009 ; 183 (1). 759-769.
29. Ouyang W., Ranganath SH, Weindel K., Bhattacharya D., Murphy TL, Sha WC, et al. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 1998 ; 9 (5). 745-755.
30. Zhang DH, Cohn L., Ray P., Bottomly K. and Ray A. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. The Journal of biological chemistry 1997 ; 272 (34). 21597-21603.
31. Ichiyama K., Yoshida H., Wakabayashi Y., Chinen T., Saeki K., Nakaya M., et al. Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. The Journal of biological chemistry 2008 ; 283 (25). 17003-17008.
32. Zhou L., Lopes JE, Chong MM, Ivanov II, Min R., Victora GD, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008 ; 453 (7192). 236-240.
33. Lassmann H. and Ransohoff RM The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] reappraisal. Trends in immunology 2004 ; 25 (3). 132-137.
34. Panitch HS, Hirsch RL, Schindler J. and Johnson KP Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987 ; 37 (7). 1097-1102.
35. Huan J., Culbertson N., Spencer L., Bartholomew R., Burrows GG, Chou YK, et al. Decreased FOXP3 levels in multiple sclerosis patients. Journal of neuroscience research 2005 ; 81 (1). 45-52.
36. Venken K., Hellings N., Thewissen M., Somers V., Hensen K., Rummens JL, et al. Compromised CD4(+) CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2007.
37. Venken K., Hellings N., Hensen K., Rummens JL, Medaer R., D' Hooghe MB, et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. Journal of neuroscience research 2006 ; 83 (8). 1432-1446.
38. Feger U., Luther C., Poeschel S., Melms A., Tolosa E. and Wiendl H. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clinical and experimental immunology 2007 ; 147 (3). 412-418.
39. Frisullo G., Nociti V., Iorio R., Patanella AK, Caggiula M., Marti A., et al. Regulatory T cells fail to suppress CD4(+)T-bet(+) T cells in relapsing multiple sclerosis patients. Immunology 2008.
40. Haas J., Hug A., Viehover A., Fritzsching B., Falk CS, Filser A., et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. European journal of immunology 2005 ; 35 (11). 3343-3352.
41. Viglietta V., Baecher- Allan C., Weiner HL and Hafler DA Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. The Journal of experimental medicine 2004 ; 199 (7). 971-979.
42. Devergne O., Coulomb-L' Hermine A., Capel F., Moussa M. and Capron F. Expression of Epstein-Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts. The American journal of pathology 2001 ; 159 (5). 1763-1776.
43. Bardel E, Larousserie F, Charlot-Rabiega P, CoulombL'Hermine A and Devergne O. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 2008 ; 181(10): 6898-6905.
44. Collison LW, Pillai MR, Chaturvedi V and Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 2009 ; 182 (10). 6121-6128.
45. Korn T. Pathophysiology of multiple sclerosis. Journal of neurology 2008 ; 255 (Suppl 6). 2-6.
46. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999 ; 5 (2). 101-104.
47. Tzartos JS, Friese MA, Craner MJ, Palace J., Newcombe J., Esiri MM, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. The American journal of pathology 2008 ; 172 (1). 146-155.
48. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nature medicine 2002 ; 8 (5). 500-508.
49. Tubridy N., Behan PO, Capildeo R., Chaudhuri A., Forbes R., Hawkins CP, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999 ; 53 (3). 466-472.
50. Brynedal B., Khademi M., Wallstrom E., Hillert J., Olsson T. and Duvefelt K. Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery? Neurobiol Dis 2009.
51. Reboldi A., Coisne C., Baumjohann D., Benvenuto F., Bottinelli D., Lira S., et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nature immunology 2009 ; 10 (5). 514-523.